Microbot Medical (NASDAQ:MBOT) Shares Pass Above 200-Day Moving Average - Time to Sell?

Key Points

• Technical move: Shares crossed above their 200‑day moving average at $2.35, trading as high as $2.51 on Wednesday with about 1.36 million shares changing hands, a bullish short‑term signal.
• Analyst sentiment: B. Riley initiated coverage with a "Buy" and the consensus rating is a "Moderate Buy" with a $7.50 average price target—well above the current share price.
• Fundamentals: Microbot is a small‑cap medical‑device company (market cap ~$158M) that remains unprofitable (negative EPS), though it marginally beat last quarter's estimate (‑$0.04 vs. ‑$0.06).

Shares of Microbot Medical Inc. (NASDAQ:MBOT - Get Free Report) crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $2.35 and traded as high as $2.51. Microbot Medical shares last traded at $2.35, with a volume of 1,360,219 shares changing hands.

Analysts Set New Price Targets

Separately, B. Riley Financial initiated coverage on Microbot Medical in a research report on Tuesday, February 10th. They set a "buy" rating for the company. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $7.50.

Microbot Medical Price Performance

The stock has a market cap of $157.83 million, a PE ratio of -8.10 and a beta of 1.19. The business has a fifty day moving average of $2.31 and a 200 day moving average of $2.35.

Microbot Medical (NASDAQ:MBOT - Get Free Report) last issued its quarterly earnings results on Thursday, March 26th. The biotechnology company reported ($0.04) EPS for the quarter, beating analysts' consensus estimates of ($0.06) by $0.02. On average, equities research analysts expect that Microbot Medical Inc. will post -0.71 EPS for the current year.

Institutional Trading of Microbot Medical

Institutional investors and hedge funds have recently bought and sold shares of the company. Cornerstone Advisory LLC acquired a new stake in Microbot Medical during the third quarter valued at approximately $30,000. American Century Companies Inc. acquired a new stake in Microbot Medical during the second quarter valued at approximately $32,000. Zacks Investment Management acquired a new stake in shares of Microbot Medical during the 3rd quarter worth approximately $33,000. Man Group plc acquired a new stake in shares of Microbot Medical during the 4th quarter worth approximately $35,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Microbot Medical during the 3rd quarter worth approximately $37,000. Institutional investors and hedge funds own 16.30% of the company's stock.

Microbot Medical Company Profile

Microbot Medical Inc NASDAQ: MBOT is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.